Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study.
P C M van de KerkhofR LoeweUlrich MrowietzM FalquesI Pau-CharlesJacek Cezary SzepietowskiPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2019)
Dimethylfumarate significantly improved DLQI outcomes vs. placebo and was not affected by baseline disease severity. Efficacy responses (PASI 50/75, PASI ≤3 and PGA 0-1) as early as Week 8 were predictive of QoL outcomes at Week 16 in DMF- and FAE-treated patients.